Vaxcyte, Inc. 宣布，其旨在预防A组链球菌所致疾病的研究性疫苗Vax-a1，已在一期临床试验中为首位健康成人受试者完成给药。该研究旨在评估Vax-a1在健康成年人群中的安全性、耐受性和免疫原性。
Vaxcyte, Inc. 宣布，其旨在预防A组链球菌所致疾病的研究性疫苗Vax-a1，已在一期临床试验中为首位健康成人受试者完成给药。该研究旨在评估Vax-a1在健康成年人群中的安全性、耐受性和免疫原性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.